Finance

Lists
Outlook: 64.5% bullish·3.2% bearish
Go to analysis
INO:NASDAQ
Inovio Pharmaceuticals Inc
1,48 USD
+1,72%
(+0,025) 1D
1,44 USD
-2,37% (-0,035)
Pre-market
Closed: 11-ноя., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
1,37 USD
High
1,48 USD
Low
1,30 USD
Mkt. cap
249,17 млн
Avg. vol.
18,79 млн
Volume
21,83 миң
52-wk high
2,72 USD
52-wk low
0,57 USD
EPS
-1,17 USD
Beta
1,71
Shares outstanding
103,40 млн
No. of employees
112
Open
1,37 USD
High
1,48 USD
Low
1,30 USD
Mkt. cap
249,17 млн
Avg. vol.
18,79 млн
Volume
21,83 миң
52-wk high
2,72 USD
52-wk low
0,57 USD
EPS
-1,17 USD
Beta
1,71
Shares outstanding
103,40 млн
No. of employees
112
News stories
From web sources and news partners
GuruFocus
GuruFocus
·
17 саат мурун
INO Reiterated by Piper Sandler -- Price Target Lowered to $6.00
Yahoo Finance
Yahoo Finance
·
1 күн мурун
Inovio Pharmaceuticals Q3 Earnings Call Highlights
TradingView
TradingView
·
1 күн мурун
Inovio Pharmaceuticals Q3 2026 Earnings Call Is Live
Yahoo Finance
Yahoo Finance
·
1 күн мурун
Inovio: Q3 Earnings Snapshot
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees112
Founded1999
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current 1,48 USD
8,00 USD (+442,37%)
Average
6,33 USD (+329,15%)
Lowest
5,00 USD (+238,98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
6,00 USD
+306,8%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
8,00 USD
+442,4%
11/06/2026
Ram Selvaraju
H.C. Wainwright
Buy
Upgraded
5,00 USD
+239%
11/02/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
13,00 USD
+781,4%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
13,33 млн
10,26 млн
14,07 млн
10,83 млн
Cost of revenue
13,33 млн
10,26 млн
14,07 млн
10,83 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,88 млн
7,22 млн
7,88 млн
7,80 млн
Operating expense
7,88 млн
7,22 млн
7,88 млн
7,80 млн
Total operating expenses
21,21 млн
17,48 млн
21,95 млн
18,62 млн
Operating income
-21,21 млн
-17,48 млн
-21,95 млн
-18,62 млн
Other non operating income
-24,27 млн
21,17 млн
4,14 млн
12,73 млн
EBT including unusual items
-45,50 млн
3,76 млн
-19,68 млн
-6,01 млн
EBT excluding unusual items
-45,52 млн
3,75 млн
-19,48 млн
-5,53 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-45,50 млн
3,76 млн
-19,68 млн
-6,01 млн
Net profit margin
-
-
-
-
Earnings per share
-0,87
-0,28
-0,31
-0,24
Interest and investment income
552,11 миң
449,34 миң
439,59 миң
363,85 миң
Interest expense
-
-
-
-
Net interest expenses
552,11 миң
449,34 миң
439,59 миң
363,85 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,86 млн
-17,14 млн
-21,63 млн
-18,30 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору